#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Complex regional pain syndrome Lymphangioma Breast angiosarcoma Infection in an immunocompromised host Mantle cell lymphoma Ewing's sarcoma Cushing's syndrome Alexander disease Non-renal cell carcinoma of kidney Glomerulonephritis Deafness bilateral Pyruvate kinase deficiency anaemia Hypersensitivity pneumonitis Congenital myopathy Gaucher's disease type I More trials…

    Learn about Rare Diseases

    Behcet’s syndrome – Diagnostics Toxic epidermal necrolysis – Life with Disease Epidermolysis bullosa – Treatment Skin angiosarcoma – Trials in Disease Fabry’s disease – Treatment Crigler-Najjar syndrome – Treatment VEXAS syndrome – Basic Information Glycogen storage disease type I Adrenogenital syndrome Immunodeficiency congenital – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Gindameran Crinecerfont BUMETANIDE Copanlisib Dihydrochloride Fludrocortisone Fidanacogene Elaparvovec Carfilzomib Pazopanib Linezolid Elasomeran Gliclazide Gsk4527226 Inupadenant Hydrochloride [11C]Az14193391 Avibactam Sodium Naloxone BENZYLPENICILLIN POTASSIUM HYDROXYCHLOROQUINE Birtamimab Eye103 More therapies…

    Learn about Your Condition

    Testicular leiomyosarcoma Relapsing multiple sclerosis Vertebrobasilar stroke Hepato-lenticular degeneration Breast cancer stage III Bile duct adenocarcinoma Chronic kidney disease Proteinuria Fallopian tube cancer Synovial sarcoma metastatic Clostridium difficile colitis Thalassaemia alpha Fragile X syndrome Testis cancer Spinal cord injury cervical More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hormone receptor positive HER2 negative breast cancer

  • Study on the Effectiveness of Abemaciclib, Inavolisib, and Giredestrant in Patients with Early HR-positive/HER2-negative Breast Cancer

    Recruiting

    2 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Giredestrant
    • Inavolisib
    • Abemaciclib
    France Greece Italy Spain

  • Study on Stopping CDK4/6 Inhibitors in Patients with Metastatic HR Positive, HER2 Negative Breast Cancer Using Abemaciclib, Letrozole, and Fulvestrant

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Abemaciclib
    • Anastrozole
    • Exemestane
    Germany

  • Study on Ribociclib and Drug Combination for Patients with Advanced HER2-Negative, Hormone Receptor Positive Breast Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    • Breast cancer female
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Anastrozole
    • Exemestane
    • Letrozole
    Germany

  • Study on Early Detection and Treatment of ER Positive HER2 Negative Breast Cancer Using Palbociclib, Fulvestrant, and Drug Combination for Patients with Molecular Relapse

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Anastrozole
    • Exemestane
    • Letrozole
    France

  • A Phase I/II Study of GVV858 Alone or in Drug Combination for Patients with Advanced Hormone Receptor‑Positive, HER2‑Negative Breast Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • GVV858
    • Goserelin
    • Letrozole
    Czechia Denmark France Germany Italy Spain

  • Study on Elacestrant for Treating ER+/HER2- Breast Cancer in Patients with ctDNA Relapse

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Elacestrant
    • Anastrozole
    • Exemestane
    Belgium Cyprus France Germany Greece Ireland +5
Previous Page
1 2 3 4 5 6 … 10
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!